Wu: Experimental binding agreed very well with their MS scoring. Showed busy table of cleavage rules from their model #AACR17
7:31am April 4th 2017 via Hootsuite
Wu: These ~250 peptide - ID new peptide motifs, IEDB compared to their MS method. Comparing their scored, netMHCPan, nM measured #AACR17
Wu: >24K HLA-assoc peptides ID 16 alleles; 1500 peptides/allele. 11% have 'signficant' changes (of 20 AAs 13 alleles 9 pos) #AACR17
7:29am April 4th 2017 via Hootsuite
Wu: They had HLA-null B-cell line, with single-allele approach, optimized nano-IP of 50M cells, create de-novo predictors #AACR17
7:28am April 4th 2017 via Hootsuite
Wu: Using Mass-spec to look at peptide (LC-MS/MS Orbitrap) - is a multi-allele approach. Interference of binding allele #AACR17
7:27am April 4th 2017 via Hootsuite
Wu: Databases - IEDB, NetMHCpanwere from heterogeneously collected datasets. Don't address 'black box' of antigen processing #AACR17
Wu: What about lower mutation load: GBM, Renal. Next: improving prediction of neoAG targets. #AACR17
7:25am April 4th 2017 via Hootsuite
Wu: Now have good AGs - what is impact of schedule, route of admin, what about co-existing tumor, combine w/other checkpoint inh #AACR17
7:24am April 4th 2017 via Hootsuite
Wu: Similar pts resp rate was only 5%. Now 12 to 24 mo post-surgery. Showed persistence, enh breadth of neoepitope responsiveness #AACR17
Wu: Mix of Stg III / IV melanoma pts - 2 Stg IV recurred shortly after vaccination; 4 doses on Pembro 'went into complete resp' #AACR17
7:22am April 4th 2017 via Hootsuite
Wu: Sorting CD4+ cels, single-cell RNA analysis pre- and post- showed major shifts in gene expression (dozens) incl metabolism #AACR17
7:21am April 4th 2017 via Hootsuite
Wu: These neoAG-reactive Tcells reacted w/autologous cells; other data shows endogenous dendritic cells #AACR17
7:20am April 4th 2017 via Hootsuite
Wu: The neoORF data validated their approach to use long peptide. NeoAG-reactive T-cells have cytolytic potential #AACR17
7:19am April 4th 2017 via Hootsuite
Wu: Their study focused on melanoma, generated four pools of long peptides. Several CD4/CD8 activated cells were 'neoORFs' #AACR17
7:18am April 4th 2017 via Hootsuite
Wu: Started with Nurses Health Study data, >600 samples WES, >20y followup #AACR17
7:16am April 4th 2017 via Hootsuite
Catherine Wu (Dana Farber MA) Using genomics in the clinic to predict / harness neoantigen biomarkers of checkpoint therapy #AACR17
7:14am April 4th 2017 via Hootsuite
Note "you millenial hoodies" - classic https://t.co/DXmVWlH8nF
9:20pm April 3rd 2017 via Hootsuite
RT @Helena_LB: Ow. My brain hurts. https://t.co/kNxlz1ogDs
8:55pm April 3rd 2017 via Hootsuite
RT @drbachinsky: Cruel fusion: What a young man’s death means for childhood cancer https://t.co/TXBtnSwn3C
7:50pm April 3rd 2017 via Hootsuite
Why Science Communication is an Essential Skill in 2017 | ACS Axial: Your Bond With Chemistry Research https://t.co/7OV8JYmKix
5:50pm April 3rd 2017 via Hootsuite
Hanahan: Reviews intestinal microbiota and cancer - stimulating the immune system. '17 rev https://t.co/aiySaJ1awy #AACR17
5:33pm April 3rd 2017 via Hootsuite
Weinberg: Non-genetically templated information. Where do cancer SCs reside along EMT spectrum? #AACR17
5:31pm April 3rd 2017 via Hootsuite
Weinberg: EMTs may reinforce its own programming; epigenetic activation. Looking at all the phenotypes: additionally cancer ones #AACR17
5:24pm April 3rd 2017 via Hootsuite
Weinberg: Normal cell differentiation survives in its long evolution to high-grade malignancy. #AACR17
5:22pm April 3rd 2017 via Hootsuite
Robert Weinberg: Nothing in cancer research should be taken 'ex cathedra', where opinions of a few dominate. #AACR17
5:21pm April 3rd 2017 via Hootsuite
@TorontoGenomics @aacr17 It's a bit of a marathon but #AACR17 continues to surprise - both people you meet and the things you learn.
5:21pm April 3rd 2017 via Hootsuite in reply to TorontoGenomics
Hanahan: For shunting terminal differentiation: "the jury is still out". Cancer stem cells w/reprogramming factors implicated #AACR17
5:17pm April 3rd 2017 via Hootsuite
Hanahan: Loss of APC in colon cancer - specific fn of blocking terminal differentiation. #AACR17
5:13pm April 3rd 2017 via Hootsuite
Hanahan: Will present present intriguing candidates w/vignettes. Consider 'shunted terminal differentiation'. Lineage plasticity? #AACR17
5:11pm April 3rd 2017 via Hootsuite
Hanahan: Acquired capabilities, two chars, tumor microenvironment. Are there additional hallmarks (and parameters) of cancer? #AACR17
5:09pm April 3rd 2017 via Hootsuite
Hanahan: #AACR17 '15 Cell updated https://t.co/lojPThnwwo Shows diagram of how drugs target each. Written up in several textbooks.
5:07pm April 3rd 2017 via Hootsuite
Hanahan: 7th - deregulating energetics, 8th avoiding immune destruction. 2nd enabling char - tumor-promoting inflammation. #AACR17
5:05pm April 3rd 2017 via Hootsuite
Doug Hanahan: Are there new hallmarks of cancer? Walks through '00 Cell https://t.co/iqys0TfqGk #AACR17
5:03pm April 3rd 2017 via Hootsuite
Evan: #AACR17 Shows rapid modulation of pancreatic epithelial cell signaling by Myc. Shows AXL kinase inh blocking proliferation in stroma
4:42pm April 3rd 2017 via Hootsuite
Evan: Turning on both - explodes. From PanIN to PDAC: is it preprogrammed? After Myc turned on, 1d-7d timecourse shown #AACR17
4:40pm April 3rd 2017 via Hootsuite
Evan: Apical Myc transcription factor: in mouse models w/switchable genetics. KRasG12D regulated by drug 1; MycERtam by drug 2 #AACR17
4:38pm April 3rd 2017 via Hootsuite
Evan: Where are the rules for a signature phenotype and genotype? Hypothesis - a metaprogram of superenhancers is being hijacked #AACR17
4:37pm April 3rd 2017 via Hootsuite
Evan: Looking at similarities - common phenotype, common genotype, common etiology, common vulnerabilities #AACR17
4:36pm April 3rd 2017 via Hootsuite
Evan: Recognizable phenotypes, yet different tissues. Pancreatic adenocarcinoma - high genetic diversity, complexity, sub-types... #AACR17
4:35pm April 3rd 2017 via Hootsuite
Gerard Evan (Univ Cambridge UK): Targeting pancreatic cancer transcription #AACR17
4:34pm April 3rd 2017 via Hootsuite
Norquist: WISP - oophorectomy delated, interval salpingectomy. Primary outcome: sexual function. Age: 30-50 https://t.co/bzjJMLMHnF #AACR17
4:31pm April 3rd 2017 via Hootsuite
Norquist: Test was with Color Genomics, reviewed outcomes, enrollment starts this month. https://t.co/bhtfu9O1NF #AACR17
4:28pm April 3rd 2017 via Hootsuite
Norquist: Looked at telephone counselling, pre- and post-genetic testing. All get online video; randomized addition of telephone #AACR17
4:27pm April 3rd 2017 via Hootsuite
Norquist: Genetic testing from 'your living room' - could be more distress, less knowledge, less likely to communicate #AACR17
4:26pm April 3rd 2017 via Hootsuite
Norquist: Also PALB2. Two prev trials - MAking GENetic Testing Accessible (MAGENTA); 1/3 of pts with hered. OvCa have no fam hist #AACR17
4:25pm April 3rd 2017 via Hootsuite
Norquist: Similar freq of FLOSSIES cohort to ExAC updated w/o TCGA, similar numbers. BRIP1, RAD51C, FAD51D are risk genes. #AACR17
4:24pm April 3rd 2017 via Hootsuite
Norquist: ExAC has flaws as a comparison gp - known ca pts are included (TCGA pts), WES only. FLOSSIES - 10K from WHI #AACR17
4:23pm April 3rd 2017 via Hootsuite
Norquist: Looked at OvCa pts, using ExAc database. https://t.co/TOubAQU1HB Showed list of genes w/no OvCa risk #AACR17
4:22pm April 3rd 2017 via Hootsuite
Norquist: DNA repair - to impact overall ovarian cancer, also reduce risk. Genetic risk assessment, prevention. 82% no mut's #AACR17
4:20pm April 3rd 2017 via Hootsuite
Barbara Norquist (Univ WA) Personalizing therapeutic choice and risk assessment for ovarian cancer #AACR17
4:12pm April 3rd 2017 via Hootsuite
